Goodpasture syndrome is a rare autoimmune disease in which your immune system produces antibodies that attack the walls of tiny blood vessels in your kidneys and lungs. It affects roughly 0.5 to 1.8 people per million each year, making it one of the least common autoimmune conditions. Despite its rarity, it can cause life-threatening kidney failure and lung bleeding if not treated quickly.
How the Disease Attacks Your Body
Your kidneys and lungs share a structural feature: both contain thin membranes called basement membranes that filter blood. These membranes are built from a protein called type IV collagen, which normally goes unnoticed by your immune system. In Goodpasture syndrome, the immune system produces antibodies (called anti-GBM antibodies) that specifically target a portion of this collagen.
Under normal conditions, the collagen molecules are tightly locked together in a shape that hides the regions the antibodies would recognize. Think of it like a lock that keeps a vulnerable surface tucked away. When that structure loosens or breaks apart, previously hidden sections become exposed. The immune system recognizes these newly visible regions as foreign, produces antibodies against them, and those antibodies deposit along the basement membranes of the kidneys and lungs. This triggers intense inflammation that damages the filtering units of the kidneys (glomeruli) and the air sacs of the lungs.
Who Gets Goodpasture Syndrome
The disease follows a bimodal pattern, meaning it tends to strike two different age groups. Younger patients, typically under 39, are more often male. Older patients, over 60, are more frequently female. A nationwide U.S. analysis found an inpatient prevalence of about 10.3 cases per million hospital admissions over a 12-year period, underscoring just how uncommon it is.
Hydrocarbon exposure, from solvents, fuels, or industrial chemicals, has been linked to the disease in some case reports, though only about 6% of documented cases involved such exposure. Cigarette smoking and respiratory infections are also considered potential triggers, particularly because any injury to the lung’s basement membrane could expose the collagen targets that set the immune reaction in motion.
Symptoms to Recognize
Goodpasture syndrome is defined by a clinical triad: rapidly worsening kidney inflammation, bleeding in the lungs, and circulating anti-GBM antibodies in the blood. In practice, the symptoms people notice first depend partly on age. Younger patients (under 30) are more likely to show up with lung symptoms, while those over 50 more often present with kidney problems alone.
Lung-related symptoms include coughing up blood (hemoptysis), shortness of breath that worsens over days to weeks, and persistent fatigue. On the kidney side, you may notice dark or tea-colored urine, reduced urine output, swelling in the legs or feet, and rising blood pressure. In one typical case report, a man in his early twenties presented with two months of worsening fatigue, recurrent hemoptysis, increasing breathlessness, and then dark-colored urine with decreased output in the final days before hospitalization.
The speed matters. “Rapidly progressive” is the key phrase clinicians use for the kidney damage in this disease. Kidney function can deteriorate over days to weeks rather than months, which is why early recognition is critical.
How It’s Diagnosed
Two tests are central to confirming Goodpasture syndrome. The first is a blood test that detects circulating anti-GBM antibodies. The second, and most definitive, is a kidney biopsy. Under a microscope with special fluorescent staining, the antibodies appear as a smooth, continuous line of IgG (a type of antibody) deposited along the walls of the kidney’s filtering capillaries. This “linear” pattern is the hallmark finding and distinguishes Goodpasture syndrome from other kidney diseases that produce a more patchy or granular pattern.
Complicating diagnosis, roughly 10 to 38% of people with anti-GBM antibodies also test positive for a second type of antibody called ANCA, which is associated with a different group of autoimmune conditions (vasculitis). When both antibodies are present, the clinical picture can overlap, and treatment decisions may need to account for both conditions.
There is also an atypical form of the disease in which the characteristic linear deposits appear on biopsy but no anti-GBM antibodies are detectable in the blood. This makes the kidney biopsy especially important when the clinical picture is suspicious but blood tests come back negative.
Treatment and What to Expect
Treatment has two goals: stop the immune attack and remove the antibodies already circulating in the blood. Corticosteroids like prednisone are used to reduce inflammation and control lung bleeding. Immunosuppressive medications are added to prevent the immune system from producing more harmful antibodies.
The cornerstone of treatment is plasmapheresis, sometimes called plasma exchange. During this procedure, blood is drawn through a needle (usually from a vein in your arm), and the liquid portion of the blood, the plasma, is separated out. Because the plasma is where the anti-GBM antibodies live, it’s discarded and replaced with healthy donor plasma before the blood is returned to your body. Most patients need plasmapheresis daily for several weeks to bring antibody levels down.
The combination of plasma exchange and immunosuppression is most effective when started before the kidneys have sustained irreversible damage. Once kidney tissue is severely scarred, it cannot regenerate, and some patients ultimately require long-term dialysis or a kidney transplant. Lung hemorrhage, while dramatic and frightening, is generally more responsive to treatment than the kidney damage.
Long-Term Outlook
Prognosis depends heavily on how much kidney function remains at the time treatment begins. Patients who start treatment while they still have some preserved kidney function have a significantly better chance of avoiding permanent dialysis. Those who already require dialysis at diagnosis face a much steeper road, though lung bleeding can still be controlled.
Goodpasture syndrome rarely recurs once the antibodies have been cleared and immunosuppression is maintained for an appropriate period. For patients who do need a kidney transplant, doctors typically wait until anti-GBM antibodies have been undetectable for at least six months before proceeding, because transplanting a kidney while antibodies are still present would put the new organ at risk for the same attack.